sr 95531 has been researched along with ganaxolone in 1 studies
| Studies (sr 95531) | Trials (sr 95531) | Recent Studies (post-2010) (sr 95531) | Studies (ganaxolone) | Trials (ganaxolone) | Recent Studies (post-2010) (ganaxolone) |
|---|---|---|---|---|---|
| 610 | 0 | 209 | 98 | 10 | 58 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chuang, SH; Reddy, DS | 1 |
1 other study(ies) available for sr 95531 and ganaxolone
| Article | Year |
|---|---|
Zinc reduces antiseizure activity of neurosteroids by selective blockade of extrasynaptic GABA-A receptor-mediated tonic inhibition in the hippocampus.
Topics: Animals; Bicuculline; Dose-Response Relationship, Drug; GABA-A Receptor Antagonists; Hippocampus; Kindling, Neurologic; Male; Mice; Microinjections; Neural Inhibition; Neurosteroids; Pregnanolone; Pyridazines; Receptors, GABA-A; Seizures; Zinc | 2019 |